KJ

Kuldeep Jagoji Dongre

Active Director Director DIN 10871198
DIN 10871198 First appointment Dec 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Kuldeep Jagoji Dongre

Data last updated:

Kuldeep Jagoji Dongre is a Director at Bestritz Pharma Private Limited (since 2024).

DIN 10871198
Primary Designation Director
First Appointment 20 Dec 2024
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Bestritz Pharma Private Limited U86100MH2024PTC436108
Director20 Dec 20242024Active

Directorship timeline

Open interactive timeline →
Bestritz Pharma Private Limited
Premium access

Shareholding and investment profile for Kuldeep Jagoji Dongre

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kuldeep Jagoji Dongre

Kuldeep Jagoji Dongre currently holds 1 directorship: Bestritz Pharma Private Limited (Director, since 20 Dec 2024).

Kuldeep Jagoji Dongre was first appointed on 20 Dec 2024 as Director at Bestritz Pharma Private Limited.

The current boards of Kuldeep Jagoji Dongre's companies include Anil Mahadeo Patil (Bestritz Pharma Private Limited), Dipankar Chudaman Bhivgade (Bestritz Pharma Private Limited), Manish Maroti Gambhir (Bestritz Pharma Private Limited), Pradnya Vinod Gambhir (Bestritz Pharma Private Limited), Raibhan Shriram Dongre (Bestritz Pharma Private Limited), Ratnakar Tularam Walde (Bestritz Pharma Private Limited), among others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available